戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 l neoplasia of grade 2 or higher [CIN2+], or genital warts).
2 e 70% of cervical cancers (CxCas) and 90% of genital warts.
3 toses, superficial basal cell carcinoma, and genital warts.
4 revents two HPV types associated with 90% of genital warts.
5 ch account for approximately 90% of external genital warts.
6 n the acquisition of urethral infections and genital warts.
7 lhydrogel was developed for the treatment of genital warts.
8 uded rates of abnormal cervical cytology and genital warts.
9 var, vaginal, and penile cancers, as well as genital warts.
10 y of diseases, including cervical cancer and genital warts.
11 uman papilloma virus cervical cell lines and genital warts.
12  (6%); gonorrhea, 5 (4%); chlamydia, 5 (4%); genital warts, 2 (1%); and pelvic inflammatory disease (
13  (12%); gonorrhea, 9 (7%); syphilis, 7 (6%); genital warts, 7 (6%); chlamydia, 5 (4%); and PID, 4 (3%
14 t and has been approved for the treatment of genital warts, actinic keratosis, and superficial basal
15    Determining the rate at which men develop genital warts after infection with alpha genus human pap
16 mulative incidence of clinically ascertained genital warts among women with incident HPV-6 or HPV-11
17 n papillomavirus (HPV)-related cutaneous and genital warts and anogenital (pre)cancer.
18          Human papillomaviruses (HPVs) cause genital warts and cancers in men.
19 evention of HPV-6-related and HPV-11-related genital warts and juvenile-onset recurrent respiratory p
20  Siripornsawan review the latest thinking on genital warts and their relation to specific viral etiol
21  of women reported ever being diagnosed with genital warts, and 1.4% of men and 3.1% of women reporte
22 ng, >10 lifetime sexual partners, history of genital warts, and among men having had receptive anal s
23                 Receptive anal sex, previous genital warts, and anal hrHPV infection were risk factor
24                              HPVs also cause genital warts, and are the most common sexually transmit
25 iverse HPVs associated with cervical cancer, genital warts, and epidermodysplasia verruciformis sugge
26 ctual perceptions regarding cervical cancer, genital warts, and HPV vaccination collected from parent
27 vaginal, and anal intraepithelial neoplasia, genital warts, and persistent and incident HPV infection
28 omaviruses types 6 and 11, the main cause of genital warts, and types 16 and 18, the main cause of ce
29 r cancer; anal cancer; head and neck cancer; genital warts; and recurrent respiratory papillomatosis.
30 anal sex (aOR, 6.23 [95% CI, 2.23-19.08]) or genital warts (aOR, 4.21 [95% CI, 1.53-11.48]) were risk
31  6/11/16/18 infection, approximately 90% for genital warts, approximately 45% for low-grade cytologic
32                         Approximately 90% of genital warts are caused by human papillomavirus (HPV) t
33                                       Benign genital warts are caused principally by the alpha10 viru
34                     Our results suggest that genital warts are common after HPV-6 or HPV-11 infection
35                    Condylomata acuminata, or genital warts, are proliferative lesions of genital epit
36 protection against both cervical cancer- and genital wart-associated types, we produced at high level
37  and their associated anogenital cancers and genital warts, but do not target betaHPV that are associ
38 rofiles and promising efficacy in preventing genital warts, cervical neoplasia, and cervical cancer.
39  clinic-based reports of a marked decline in genital warts diagnoses among young people in Australia
40                                              Genital wart (GW) incidence is high among men.
41                                     Notably, genital warts (GW) are the first observable clinical out
42                             More than 90% of genital warts (GW) cases are caused by human papillomavi
43                                 Diagnoses of genital warts (GW) in genitourinary medicine (GUM) clini
44  the risk of cancer among men and women with genital warts (GW).
45 n this cohort study, we assessed the risk of genital warts (GWs) according to timing and number of do
46 e nationwide, real-world data on the risk of genital warts (GWs) after <3 vaccine doses.
47  of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the
48 istory of human papillomavirus (HPV)-related genital warts (GWs) in men are sparse.
49              A reduction in the incidence of genital warts (GWs) is one of the first markers of the e
50 e etiological agents of approximately 90% of genital warts (GWs).
51 al candidiasis, pelvic inflammatory disease, genital warts, herpes simplex virus infection, syphilis,
52 ical cancers (HPV 16, 18, 31, and 45) and in genital warts (HPV 6 and 11).
53 heat treatment correlated with regression of genital warts in a subset of patients, including at dist
54 and Human Papillomavirus (HPV) infection and genital warts in men.
55                      The 24-month cumulative genital wart incidence was 57.9% (95% confidence interva
56 he infection and with abnormal Pap tests and genital warts; it was negatively associated with marriag
57 eat various infectious skin diseases such as genital warts, keratosis, and basal cell carcinoma.
58  Eligibility criteria included no history of genital warts or HIV infection.
59           Eligibility included no history of genital warts or human immunodeficiency virus.
60  a woman within the past year, no history of genital warts or penile or anal cancer, and no current d
61 no evidence of an association with prevalent genital warts (OR, 0.93, 95% CI, 0.65-1.33; 15 studies).
62 ich may play a major role in its activity in genital wart patients.
63                   Twenty-seven subjects with genital warts received 3 immunizations over 4 weeks in a
64 PV) type 6 (HPV-6) and HPV-11, induce benign genital warts that rarely progress to malignancy.
65 nother topical immunomodulator, approved for genital wart treatment in adults, has also been examined
66  qHPV was 1.0/100PY (95% CI, 0.3-2.6) and of genital warts was 1.0/100PY (95% CI, 0.3-2.5).
67 onfidence interval [CI], 1.1-4.1), and IR of genital warts was 2.3/100PY (95% CI, 1.2-4.1).
68 s between 1999-2011 involving a diagnosis of genital warts were obtained from a comprehensive nationa
69 onged rupture of membranes, and a history of genital warts were significantly associated with transmi